Endometriosis Medicines – Your 2016 Guide to Sales Potentials of that Rising, Underserved Female Health Market What does the future hold for treating endometriosis, a common disease? Our new analysis forecasts sales of drugs treating that menstrual cycle disorder. Visiongain’s report gives predictions to 2026 at overall world market, product and national level.
Avoid falling behind in data or losing influence. Instead discover what progress, opportunities and increasing revenues endometrial therapies face. There you also explore trends, results, R&D and events, assessing commercial prospects.
Read on, then, to explore endometriosis treatments, including hormonal therapy. See below what future revenue that expanding pharmaceuticals market could generate.
Forecasts and other analysis to benefit your research, assessments, plans and decisions 10% of women worldwide have endometriosis, giving high, rising demand for those medicines. New drugs appear and promising candidates reach clinical trials. Discover, from 2016, what revenues and other progress are possible in that expanding market.
Besides sales forecasting to 2026, our survey shows recent results, growth rates and market shares. There you find original analysis. You also assess research and development. The study gives 53 tables, 61 charts and a research interview.
Our report’s purpose is to help your research, analyses and decisions on the endometriosis drugs industry and market. Our work also benefits your authority and reputation for commercial insight, helping you compete and succeed.
The following sections explain how our new investigation benefits your work.
Predictions of drug sales – what is possible for those gynaecological medicines? How will endometriosis medicines perform from 2015 to 2026 at world level? Our study forecasts revenues of these five brands: • Lupron • Eligard • Zoladex • Depo-Provera • Visanne.
Our analysis shows how products can compete and succeed. There you investigate trends, exploring challenges, changes and opportunities. See what is possible.
Discover what the future holds for endometriosis drugs and their developers, producers and marketers.
Endometriosis R&D holds high potential – explore advances, assessing prospects That therapeutic segment holds much promising research and development. The new gonadotropin-releasing hormone (GnRH) antagonist approach to treat endometriosis may take over from the present GnRH agonist drugs, our study notes.
There exists great scope for new and improved medicines, benefiting pharma companies, healthcare providers and patients. Explore, from 2016, what is possible, staying ahead in knowledge to benefit your work.
Our report also shows you geographical sales predictions.
National markets – what is possible for those gynaecological drug revenues? Advances in biopharma expand the range and use of endometriosis-treating drugs. Our study shows you individual revenue forecasts to 2026 for 11 national markets: • US • Japan • Germany, France, Italy, Spain, UK (EU5) • China, Brazil, India, Russia (BRIC).
That way you assess countries and regions with highest revenues and potential sales growth. See what is possible, from 2016, in developed and developing countries.
That market gains momentum from rising disease prevalence, new and improved drugs and other forces stimulating treatment demand in that under-served market.
Influences, events and changes affecting companies treating endometriosis Explore issues affecting that market, including these forces: • Incidence and prevalence of that disorder, an often overlooked condition • Raising disease awareness and overcoming reimbursement challenges • Improving diagnosis and treatment of endometriosis – new therapies controlling hormones responsible for the build-up of endometrial tissue • Hormone therapy, pain relievers (e.g. NSAIDs), contraceptives, medical devices and surgical options.
And gain insight on these developments, among others: • Prospects for leading and emerging national markets – what the future holds for treating those vast patient populations • Oral drug delivery for endometriosis – new therapies and novel drug candidates extend therapeutic and commercial potentials of that market • Industry collaborations and R&D activities that stimulate progress.
In our report you also gain SWOT and PEST analysis, assessing what drives and restrains that expanding female health market.
That way you discover what is possible for leading pharma companies and specialists. Why miss out? Instead explore what the future holds for treating endometriosis, seeing the gains possible.
Leading companies and overall 2020 market value – what revenues are possible? Our work predicts the world market for those drugs will reach $1.92 billion in 2020. That market will expand from 2016 to 2026. With our analysis you discover how high sales can go, seeing what is possible for those drug companies.
That way you assess what organisations hold most potential. Those companies include these organisations: • AbbVie • Pfizer • Bayer HealthCare • AstraZeneca • Astellas • Takeda.
Discover what the future holds for participants in that industry, exploring what they do, as well as their commercial potentials.
6 ways Endometriosis Drug Forecasts and R&D 2016-2026 helps your work Our new investigation benefits your work in these six main ways, helping you stay ahead in knowledge and benefit your authority: • Revenues for endometriosis drugs at overall world level to 2026 – assess scope for investments, developments, production and marketing • Leading products’ sales to 2026 – discover predicted revenues of 5 prominent drugs, seeing how those medicines can compete and succeed • National market forecasting to 2026 for 11 leading countries – explore the best regions for treatment demand, sales and revenue expansion • Research and development – see progress, trends and prospects in that gynaecological R&D, assessing opportunities and possibilities • Leading companies, news and opinion – examine participants in that rising market, gaining insight to help you stay ahead and succeed • Analysis of what stimulates and restrains that market – assess challenges and strengths, helping you compete and gain advantages.
That analysis, by our in-house team in the UK, gives knowledge to benefit your research, plans, decisions and proposals. It shows data you find nowhere else.
Predictions for that female reproductive disorder – benefit your reputation for insight With our independent study you assess products, companies, progress and possibilities for that female reproductive medicine. There discover the best commercial opportunities, as well as ways to help patients. See what is possible.
Having our analysis means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how to save time and effort, also benefiting your plans, decisions, presentations, proposals and influence.
Try that study, staying ahead. Our investigation of Endometriosis Drugs Forecast shows you market data, trends, opportunities for that large, expanding female healthcare market. So avoid missing out – please get our new report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview
1.1 Endometriosis Drugs: Industry and Market Review
1.2 Benefits of This Report
1.3 How This Study Delivers
1.4 Main Questions This Work Answers
1.5 Who is This Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Some Related Reports
1.9 About Visiongain
2. Introduction to Endometriosis and its Treatment
2.1 What is Endometriosis?
2.2 Incidence and Prevalence of that Female Disorder
2.3 The Endometriosis Drug Market, 2014
2.4 PEST Analysis
2.4.1 Political Factors
2.4.2 Economic Factors
2.4.3 Social Factors Affecting the Endometriosis Therapies Market
2.4.4 Technological Developments in Endometriosis Treatment
2.5 Market Growth Drivers and Restraints
2.6 Outlook for the Endometriosis Drugs Market, 2015-2026
3. Leading National Markets: Outlooks, 2016-2026
3.1 Endometriosis Treatment by Therapy
3.1.1 Hormones
3.1.2 Painkillers
3.1.3 Surgical Treatment
3.2 Endometriosis Leading National Markets, 2016-2026
3.2.1 Leading National Markets: The US Dominated in 2014
3.2.2 What is The Future for Leading National Markets?
3.2.3 The US Endometriosis Market, 2016 to 2026
3.2.4 EU5 Endometriosis Market, 2016 to 2026
3.2.4.1 The UK Endometriosis Market, 2016 to 2026
3.2.4.2 French Endometriosis Market, 2016 to 2026: Steady Growth Throughout the Forecast Period
3.2.4.3 German Endometriosis Market, 2016 to 2026: Largest Market Share in European Union
3.2.4.4 Spanish Endometriosis Market, 2016 to 2026
3.2.4.5 Italian Endometriosis Market, 2016 to 2026
3.2.5 Japanese Endometriosis Market, 2016 to 2026: Second Largest in the World
3.2.6 Chinese Endometriosis Market, 2016 to 2026
3.2.7 Indian Endometriosis Market, 2016 to 2026: Fast Growing Market
3.2.8 Brazilian Endometriosis Market, 2016 to 2026
3.2.9 Russian Endometriosis Market, 2016 to 2026
4. Leading Drugs in the World Endometriosis Market, 2015
4.1 Lupron: The Leading Endometriosis Drug in the Market
4.1.1 Profile
4.1.2 Lupron Historical Revenue
4.1.3 Lupron Revenue Forecast, 2016-2026
4.2 Eligard: Facing Challenges When Patent Expires
4.2.1 Profile
4.2.2 Eligard Historical Revenue
4.2.3 Eligard Revenue Forecast, 2016-2026
4.3 Zoladex
4.3.1 Profile
4.3.2 Zoladex Historical Revenue
4.3.3 Zoladex Revenue Forecast, 2016-2026
4.4 Depo-Provera
4.4.1 Profile
4.4.2 Depo-Provera Historical Revenue
4.4.3 Depo-Provera Forecast, 2016 to 2026
4.5 Visanne: First Oral Treatment for Endometriosis by Bayer
4.5.1 Profile
4.5.2 Visanne Historical Revenue
4.5.3 Visanne Forecast, 2016 to 2026
5. Research and Development for Endometriosis Drugs
5.1 Industry Collaboration and R&D Activities
5.1.1 Investigational Drug Treatment for Endometriosis
5.2 Companies Involved in Producing Drugs for Endometriosis
5.3 AbbVie: Leading Producer of Endometriosis Drugs
5.3.1 Company Description
5.3.2 Business Segmentation
5.3.3 AbbVie Revenue Performance, 2014
5.3.4 Product in Pipeline: Elagolix, Oral Drug
5.4 Pfizer
5.4.1 Company Description
5.4.2 Business Segmentation
5.4.3 Pfizer Revenue Performance, 2014
5.5 Bayer HealthCare: Visanne Showing Faster Growth in Revenue
5.5.1 Company Description
5.5.2 Business Segmentation
5.5.3 Bayer HealthCare Revenue Performance, 2014
5.5.4 Four Drug Candidates in Product Pipeline
5.6 AstraZeneca
5.6.1 Company Description
5.6.2 Business Segmentation
5.6.3 AstraZeneca Revenue Performance, 2014
5.7 Astellas
5.7.1 Company Description
5.7.2 Business Segmentation
5.7.3 ASP1707 an Oral Dosage Form: Product in Pipeline
5.8 Takeda
5.8.1 Company Description
5.8.2 Business Segmentation
5.8.3 Product in Pipeline: Relugolix- Oral Form
5.9 Repros Therapeutics
5.9.1 Company Description
5.9.2 Business Segmentation
5.9.3 Product in Pipeline: Proellex in Phase II Trials
5.10 Euroscreen
5.10.1 Company Description
5.10.2 Business Segmentation
5.10.3 Product in Pipeline: ESN364 Has Entered Into Phase II Trials
5.11 Kissei Pharmaceutical
5.11.1 Company Description
5.11.2 Business Segmentation
5.11.3 Product in Pipeline: KLH-2109 Exclusive Rights Given to ObsEva
5.12 Addex Therapeutics
5.12.1 Company Description
5.12.2 Product in Pipeline
6. Qualitative Analysis of the Endometriosis Drugs Market
6.1 SWOT Analysis: Future Scope of the Market
6.2 Strengths of the Market
6.2.1 Vast, Expanding Ageing Population
6.2.2 A Number of Promising Drug Candidates
6.2.3 Secondary Indications
6.3 Weaknesses
6.3.1 Lack of Disease Awareness
6.3.2 Reimbursement Issues
6.3.3 Demand for Better Diagnosis and Treatment of Endometriosis
6.4 Opportunities
6.4.1 Rising Disease Prevalence
6.4.2 Increased Demand in Market
6.4.3 Novel Mechanisms and Delivery Methods
6.5 Threats
6.5.1 Competition from Generic Drugs
6.5.2 Governments Limiting Healthcare Spending
7. Research Interview
7.1 Interview with Mr Kumar Kunde, Consultant Obstetrician and Gynaecologist, Guy's and St Thomas' Private Healthcare, UK
8. Conclusions from the Research and Analysis
8.1 Future of the Endometriosis Pharmaceuticals Market
8.2 The US Will Remain the Largest National Market from 2016 to 2026
8.3 Trends in the Endometriosis Treatments Market
List of Tables
Table 1.1 Endometriosis Drug Sales: Leading National Markets, Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 1.2 Currency Exchange Rate to $US
Table 2.1 Prevalence of Endometriosis in Women: Leading Countries, 2014
Table 2.2 Global Endometriosis Market Revenue Performance: Revenue ($bn) and AGR (%), 2012-2014
Table 2.3 Political, Economic, Social and Technological Factors (PEST) Affecting Endometriosis Market, 2016
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Automation is a rising trend in the supply chain as a way to reduce time to market and enhance efficiency. Automation is appealing for a variety of reasons, the most important of which is that it reduces human contact and hence interference.
From a long-term perspective, the rapid growth of the mid-class economy will enhance the demand for OTC products in emerging economies such as China, India and Brazil.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
